NRG1 and pancreatic adenocarcinoma: In this study, most fusion-positive patients were identified by RNA-NGS, and the study resulted in the recent FDA approval of zenocutuzumab in December 2024 for patients with NSCLC and pancreatic adenocarcinoma harboring NRG1 fusions (33).